ESC 365 - Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial

ESC Premium Access

Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial

Session: Progress in anticoagulation for venous thromboembolism

Topic: Venous Thromboembolism

Speaker: Doctor A. Kalayci Karabay (Boston, US)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Doctor Arzu Kalayci Karabay

Harvard Medical School, Boston (United States of America)

0 follower

3 more presentations in this session

State of the Art - Optimizing the prevention of venous thromboembolism

Speaker: Professor A. Spyropoulos (New York, US)

Asian patients versus non-Asian patients in the efficacy and safety of direct oral anticoagulants relative to vitamin K antagonist for venous thromboembolism: a systemic review and meta-analysis

Speaker: Doctor Y. Yamashita (Kyoto, JP)

Predictive value of VTE-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with venous thromboembolism: results of the XALIA study

Speaker: Doctor E. Klok (Leiden, NL)

Access the full session

Progress in anticoagulation for venous thromboembolism

Speakers: Doctor A. Kalayci Karabay, Professor A. Spyropoulos, Doctor Y. Yamashita, Doctor E. Klok

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources